WHICH COUNTRY STANDS WHERE IN THE DEVELOPMENT OF COVID-19 VACCINE?

Development of Covid-19 Vaccine-

• The number of Covid-19 cases across the world has crossed 15 million, and over 617k died. The entire world is trying to find a vaccine to check the spread of Covid-19.
• Many countries including US, China, Russia, India, UK, Germany, and Australia are working on vaccines in various stages of development.
• More than 150 vaccines are under various stages of testing across the world.

|Also read: How to stay immuned during Covid-19?

                  Is Bubonic plague another pandemic?

CHINA:

China is speeding up to race in the development of vaccines with Sinovac Biotech’s experiment which became China’s second and world’s third vaccine to enter the final stage testing.

Even if China emerged as a sluggard in the covid-19 vaccine development, one of the vaccines amongst the four was recently found safe in the final stage human trial.

In order to speed up the experimental stage, China allowed Sinopharm and Sinovac to combine Phase I and Phase II trials. These vaccines mainly focus on inactivated vaccine technology. The Sinovac vaccine first dose was given to 15,000 registered volunteers in Abu Dhabi. After the second dose, The researchers saw development of antibodies in the bodies of the volunteers.

But China has to face a lot of challenges as not many countries are agreeing to conduct large scale vaccine trials with it. Recently, the Bangladesh Medical Research Council (BMRC) has given the approval to the last stage trial by the Chinese vaccine in their country.

|Click here: Sinovac Vaccine

UNITED KINGDOM:

UK is leading the list of vaccines with two candidates, out of which the vaccine developed by the Oxford University in partnership with AstraZeneca is currently in large scale Phase III human trials.

The vaccine developers published their first phase study data in the medical journal ‘The Lancet’.

According to Oxford researchers, the experimental vaccine provides ‘double protection’ from the novel coronavirus following early stage human trials. Scientists stated that the vaccine has shown results that it can both produce antibodies and cell-mediated immune responses.

In terms of development, ChAdOx1 nCoV-19 vaccine is reviewed as the most advanced candidate against COVID-19. Scientists hope that this candidate will make the human body recognize and develop an immune response to the spike glycoprotein, which will help stop the SARS-CoV-2 virus from entering the human cells.

The name of the vaccine is expected to be called ‘Covishield’ in the market which would be priced at 1000 or less as per the reports.

|Click here: Lancet journal-pdf

 

UNITED STATES:

After receiving approval to conduct the Phase II trials from FDA (US Food and Drug Administration), the Moderna biotech company is preparing to conduct final stage by July 27, as per source. This vaccine has already conducted Phase I trials in Seattle, which was tested on 45 healthy volunteers, injected 28 days apart.

The Novavax vaccine candidate has also shown promising results. After showing great results in baboons and mice, the biotech company will conduct human trials in Australia on 150 volunteers as per reports.

|Click here: Globenewswire-Novavax to Present COVID-19 Vaccine Candidate-2nd ISV COVID 19 Vaccines

RUSSIA:

While the rest of the world is working on the vaccines in limelight, Russia out of nowhere ventured into the list and outshines in the race.

A top Russian official stated that the country is racing to roll out a vaccine by September after knowing whether the vaccine candidate would work effectively or not at the end of the three months of trials.

The Moscow State Medical University reported that the trials started on June 18, the first batch of the volunteers were discharged on July 15 .

|Click here: RealReport-Twitter

sputniknews-clinical trials of russian covid-19 vaccine

sputniknews-second phase trial of russian covid-19 vaccine

 

INDIA:

The Drugs Controller General of India (DCGI) has permitted two indigenous vaccine candidates, developed in India- one by the Bharat Biotech International Limited and ICMR and another by Zydus Healthcare Limited, standing at Phase I and Phase II clinical human trials respectively.

 India started the human trials of Covaxin which has been jointly developed by Bharat Biotech and Indian Council of Medical Research (ICMR). The Indian Government has also allocated Rs 100 crore from the PM-CARE funds to support the production of the vaccines.

Under the leading role of Indian pharmaceutical productions, SERUM Institute of India is planning to produce around 1-2 million of doses of the Oxford vaccine by August.

|Click here: @BharatBiotech-Twitter

clinicaltrialsarena news-zydus covid19